Skip to search formSkip to main contentSkip to account menu

cytarabine/etoposide

Known as: ARA-C/VP-16 
A combination of agents containing cytarabine and etoposide.
National Institutes of Health

Related topics

Related topics

2 relations
CytarabineEtoposide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
High-dose of daunorubicin as induction treatment for adults with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia.
6589 Background: Although daunorubicin (D) has been used as major part of induction treatment for adult acute lymphoblastic… 
2007
2007
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis.
7595 Background: There is currently no consensus on the optimal treatment for patients diagnosed with primary CNS lymphoma (PCNSL… 
2006
2006
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis
7595 Background: There is currently no consensus on the optimal treatment for patients diagnosed with primary CNS lymphoma (PCNSL… 
2006
2006
Cytarabine/etoposide/granulocyte colony-stimulating factors
  • 2006
  • Corpus ID: 195108447
2005
2005
Low dose involved field radiation (IFRT) or no further treatment following complete response to initial chemotherapy in young adult (YA) patients 16–21 years of age with Hodgkin’s disease (HD): The…
8513 Background: There is scant data in the literature concerning the outcome of YA pts 16–21 years of age with HD. Methods… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)